Find a Clinical Trial

Showing 1 - 10 of 34 Trials
  • Principal Investigator:

    Julian Adin Abrams, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    NA
    This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing. The time of involvement for an individual will range from 2 weeks to 2 months, depending on the results of the Cytosponge test and time to follow up endoscopy, if indicated. The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the...
  • Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans. Are you Eligible? (Inclusion Criteria) ≥18 years old have locally advanced or metastatic CRC, GI, or esophageal cancer(s) Life expectancy ≥12 weeks able to swallow oral medications
  • Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This study is being done to answer the following question: What is the highest dose of BAY 1895344 and FOLFIRI chemotherapy (irinotecan, 5- fluorouracil, which is also known as 5-FU, and leucovorin) in combination that can be safely and tolerably taken in patients with advanced gastrointestinal cancer? This is the first time that these drugs will be tested together in humans. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your cancer. The usual approach is defined as care most people get for advanced gastrointestinal cancer...
  • Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    II
    The purpose of this research study is to test the experimental drug, SAR444245, in combination with other anticancer therapies, cetuximab or pembrolizumab, for the treatment of advanced or metastatic gastrointestinal cancer. SAR444245 will also be combined with one anticancer therapy, pembrolizumab, that belongs to a class of therapies called immune checkpoint inhibitors (ICI- type of drug that blocks proteins called checkpoints that are made by immune system cells and some cancer cells) that is already approved for the treatment of these conditions. Investigational means that the drug has...
  • Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    This study is designed to test different doses of FLX475 to see if it is safe and to study how the drug is absorbed and how the human body gets rid of the drug. The study will test FLX475 alone and in combination with pembrolizumab, a drug already approved by the United States Food and Drug Administration (FDA) for the treatment of patients with certain types of cancers. Pembrolizumab also works to stimulate your immune system and is also known as a checkpoint inhibitor. The objective of the study is to assess the safety and activity of FLX475 alone and FLX475 in combination with...
  • Principal Investigator:

    Bret Taback, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    NA
    Surgery is the main treatment for many cancer conditions. In many elderly patients, surgery can greatly affect physical condition, and the ability to return to pre-surgery levels of physical functioning. By providing some simple pre-surgical recommendations, it may be possible to improve the rate of recovery from surgery and the possibility that patients will return to their pre-surgery levels of function. Your doctors are participating in a study to determine if a change in how they evaluate and manage elderly patients will improve recovery rates from major cancer surgery. Doctors and...
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced solid tumor or urothelial carcinoma. The usual approach is defined as care most people get for advanced solid tumors or urothelial carcinoma. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your general health after receiving multiple doses of BMS-986340 alone or together with nivolumab. BMS-986340 is an immunotherapy antibody and an investigational research drug. Investigational drugs are drugs that are not yet approved by the Food...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to learn about the study drug BDC-1001 in patients with HER2-expressing tumors. Researchers will be studying the use of BDC-1001 alone as well as in combination with Pembrolizaumab. This study will help researchers learn if the study drug can help with HER2-expressing tumors and how people respond to the drug. The researchers of this study will be looking at the safety, efficiency, and tolerability of BDC-1001, as well as how the body absorbs, breaks down, and removes the drug in patients with advanced HER2-expressing solid tumors. This research study will be the...
  • Principal Investigator:

    Brian Henick, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are approved by the United States Food and Drug Administration (FDA). The vaccine is specific to you and your tumor, and cannot be used to treat any other patients. Are you Eligible? (Inclusion Criteria) Do you have bladder, colon stomach, lung,...

Pages